P11.21.a Long-term Survival With Idh Wildtype Glioblastoma: First Results From the Eternity Brain Tumor Funders’ Collaborative Consortium (eortc 1419)
Year: 2023
Type: conference-abstract
Abstract: BACKGROUND Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. METHODS European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and by the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumors, prognostic factors were analyzed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. RESULTS At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterized) had been registered. In the IDH wildtype population, median age was 56 years (range 24-78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumors with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% CI 7.9-11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p<0.001) and had a high rate (48.8%) of MGMT promoter unmethylated tumors. CONCLUSION s Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.
Source: Neuro-Oncology
Authors: M Weller, J Felsberg, D Gramatzki, E Le Rhun, J Clarke, R Soffietti, W Wick, O Chinot, F Ducray, P Roth, K McDonald, P Hau, A F Hottinger, J Reijneveld, O Schnell, C Marosi, M Glantz, A Darlix, G Lombardi, D Krex, M Glas, D A Reardon, M J van den Bent, F Lefranc, U Herrlinger, E Razis, A F Carpentier, S Phillips, R Rudà, A Wick, E Tabouret, D Meyronet, C Maurage, E Rushing, R Rapkins
Institutions: University Hospital Zurich, Düsseldorf University Hospital, University of California, San Francisco, University of Turin, University Hospital Heidelberg, Assistance Publique Hôpitaux de Marseille, Hospices Civils de Lyon, UNSW Sydney, University Hospital Regensburg, Centre Hospitalier Universitaire Vaudois, University Medical Center Freiburg, Medical University of Vienna, Pennsylvania State University, Azienda Ospedale - Università Padova, University Hospital Carl Gustav Carus, Essen University Hospital, Dana-Farber Cancer Institute, Erasmus MC, University Hospital Bonn, Hygeia Hospital, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Lille
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4386537643